Intuitive Surgical vs. Abbott: Which Medical Technology Stock Offers Greater Potential Today?

Intuitive Surgical and Abbott Laboratories: A Comparative Overview

Both Intuitive Surgical (ISRG) and Abbott Laboratories (ABT) wrapped up 2025 with robust fourth-quarter results. However, their future growth paths are expected to diverge as they pursue different strategies.

Intuitive Surgical is concentrating on expanding its procedure volumes, leveraging its extensive da Vinci system installations and ongoing technological advancements. Meanwhile, Abbott is set to capitalize on its broad device portfolio, strong position in diabetes management, and a rich pipeline in cardiovascular and diagnostic products. Although both companies anticipate steady growth through 2026, their operational approaches are distinct.

This analysis will explore the competitive strengths of each company to help determine which may be better suited for inclusion in your investment portfolio.

Why Intuitive Surgical Stands Out

Intuitive Surgical’s growth is primarily fueled by increased procedure volumes. In 2025, global da Vinci procedures climbed by roughly 18%, surpassing 3.1 million, with the U.S. market up 15% and international markets growing 23%. The company’s total revenue rose 21%, and recurring revenue—which made up 81% of fourth-quarter sales—grew 20%.

Recurring revenue, mainly from instruments, accessories, and services, expanded in tandem with procedure growth, supported by a 12% increase in the installed base to over 11,100 da Vinci systems. Utilization rates improved, particularly with the adoption of the da Vinci 5, which offers enhanced efficiency and greater case throughput.

In 2025, Intuitive Surgical placed 1,721 da Vinci systems, including 870 of the latest da Vinci 5 models, reflecting strong demand for upgrades and international expansion. The company projects procedure growth of 13-15%, accounting for macroeconomic challenges like capital limitations in Europe and rising competition in China. Despite tariff pressures, operating margin for the year increased by 70 basis points to 37%, demonstrating strong operational leverage.

Innovation remains central to Intuitive Surgical’s strategy. The company is accelerating the rollout of da Vinci 5, broadening its Force Feedback instrument range, seeking cardiac procedure approvals, and advancing imaging technologies, including AI enhancements and upcoming hyperspectral imaging capabilities expected in 2026.

Beyond the da Vinci platform, Ion procedure volumes surged 51% in 2025, with nearly 1,000 systems installed, highlighting the company’s expanding reach beyond core soft-tissue robotics. Management believes that robotic surgery adoption is still in its early stages, suggesting significant room for future growth.

Analyst consensus for ISRG’s 2026 earnings per share has increased by $0.48 over the past three months.

Abbott Laboratories: Diversified Growth Engine

Abbott Laboratories achieved broad-based growth in its device segment, with Medical Devices sales rising 10.5% in the fourth quarter. Diabetes Care CGM revenues led the way with 12% growth, marking the third consecutive year of over $1 billion in annual CGM sales. The company expects this segment to continue expanding at a low double-digit rate in 2026.

Cardiovascular businesses, such as Structural Heart and Electrophysiology, also posted strong double-digit gains, driven by products like Volt PFA and Navitor. In Diagnostics, Core Laboratory revenues increased 3.5% (excluding China), while the impact of declining COVID testing continued to ease.

Nutrition segment revenues fell due to pricing and volume pressures, but management anticipates a rebound in the second half of 2026. Abbott reported 12% adjusted EPS growth in the fourth quarter and forecasts 6.5-7.5% organic sales growth and about 10% EPS growth at the midpoint for 2026, supported by a 50-70 basis point improvement in operating margin.

Abbott’s diverse operations across devices, diagnostics, nutrition, and emerging market pharmaceuticals are expected to support ongoing high single-digit growth.

Consensus estimates for ABT’s 2026 earnings per share have increased by $0.01 in the past 90 days.

Stock Performance and Valuation: ISRG vs. ABT

In the past year, Intuitive Surgical’s share price declined by 9.9%, while Abbott’s fell by 15.2%. During the same period, the broader Medical sector gained 1.4% and the S&P 500 Index rose 21.4%.

From a valuation perspective, Abbott appears more attractively priced. Its forward price-to-earnings ratio stands at 19.91, compared to 49.41 for Intuitive Surgical.

Which Is the Better Investment?

Abbott Laboratories offers steady, diversified growth, with particular strength in diabetes and cardiovascular devices, though its Nutrition segment faces short-term challenges. Intuitive Surgical, on the other hand, is accelerating growth through rising procedure volumes, a growing installed base, and continuous innovation, resulting in a higher proportion of recurring revenue.

While Abbott provides defensive stability through its diversified business model, Intuitive Surgical’s consistent double-digit procedure growth, high recurring revenue, and ongoing platform enhancements make it a more compelling long-term growth opportunity. Currently, Intuitive Surgical holds a Zacks Rank #1 (Strong Buy), whereas Abbott Laboratories is rated Zacks Rank #3 (Hold).